Theravance Biopharma Inc reports results for the quarter ended in June - Earnings Summary

Theravance Biopharma

05/08/2024 22:02

* Theravance Biopharma Inc  TBPH.OQ  reported a quarterly
adjusted
loss of 28 cents​​ per share for the quarter ended in June,
identical to the same quarter last year.  The mean expectation
of four analysts for the quarter was for a loss of 21 cents per
share. Wall Street expected results to range from -24 cents
to -19 cents per share.
    * Revenue rose 3.7% to $14.26 million from a year ago;
analysts
expected $15.45 million. 
    * Theravance Biopharma Inc's reported EPS for the quarter
was a
loss of 34 cents​.
    * The company reported a quarterly loss of $16.53 million.
    * Theravance Biopharma Inc shares had risen by 13.7% this
quarter and lost 14.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Theravance
Biopharma Inc is $15.00 
This summary was machine generated from LSEG data August 5 at
09:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.21          -0.28          Missed
 Mar. 31 2024      -0.25          -0.24          Beat
 Dec. 31 2023      -0.15          -0.17          Missed
 Sep. 30 2023      -0.21          -0.17          Beat